Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Recombinant Interleukin-12 Hepatocellular Carcinoma	CNBG-Virogin Biotech (Shanghai) Ltd.	P1/2	CCC (54)
Retifanlimab Metastatic Malignant Neoplasm	Incyte Corporation	P1/2	CCC (54)
Rintatolimod Breast Cancer	Roswell Park Cancer Institute	P1/2	CCC (54)
Rmc-6236 Digestive System Cancer	Amgen	P1/2	CCC (54)
Ruxolitinib Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome	Jennifer Saultz	P1/2	CCC (54)
Samuraciclib Pancreatic Ductal Adenocarcinoma	University Health Network, Toronto	P1/2	CCC (54)
Selinexor Triple-Negative Breast Carcinoma	National University Hospital, Singapore	P1/2	CCC (54)
Selinexor Non-Hodgkin Lymphoma	Mayo Clinic	P1/2	CCC (54)
(-)-SIRPIGLENASTAT Fibrolamellar Hepatocellular Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P1/2	CCC (54)
sr604 Factor VII Deficiency	Shanghai RAAS Blood Products Co., Ltd.	P1/2	CCC (54)
TIL Effects of Immunotherapy	Shanghai Juncell Therapeutics	P1/2	CCC (54)
Trastuzumab Deruxtecan Gastric Cancer	National Cancer Institute (NCI)	P1/2	CCC (54)
Trastuzumab Deruxtecan Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8	National Cancer Institute (NCI)	P1/2	CCC (54)
Trastuzumab Deruxtecan Gastric Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Upifitamab Rilsodotin Non-Small Cell Lung Carcinoma	Mersana Therapeutics	P1/2	CCC (54)
Venetoclax Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	OHSU Knight Cancer Institute	P1/2	CCC (54)
Venetoclax Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable	OHSU Knight Cancer Institute	P1/2	CCC (54)
Venetoclax Primary Myelofibrosis	OHSU Knight Cancer Institute	P1/2	CCC (54)
Vistusertib Triple-Negative Breast Carcinoma	Queen Mary University of London	P1/2	CCC (54)
Ziftomenib Acute Myeloid Leukemia With 11q23 Abnormalities	Massachusetts General Hospital	P1/2	CCC (54)
Zimberelimab Pancreatic Adenocarcinoma	Jonsson Comprehensive Cancer Center	P1/2	CCC (54)
Zofran Lymphoma, B-Cell	Mayo Clinic	P1/2	CCC (54)
[203pb]vmt01 Cutaneous Melanoma	Perspective Therapeutics	P1/2	CCC (53)
Acalabrutinib Prolymphocytic Leukemia	Acerta Pharma BV	P1/2	CCC (53)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Acute Lymphoblastic Leukemia	David Wald	P1/2	CCC (53)

Showing 376 to 400 of 8,400 assets

PreviousPage 16 of 336Next